{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Status:
Investigational
Source:
NCT02350426: Phase 1 Interventional Terminated Arthritis, Rheumatoid
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Flutriciclamide F18 (18F-GE-180), a translocator protein (TSPO)-PET radiotracer was used using in different pathologies. This agent was studied in phase I clinical trial to assess inflammation in rheumatoid arthritis. However, this study was terminated because of the pre-defined stopping criteria in the protocol.
Status:
Investigational
Source:
INN:fluorfenidine (¹⁸F) [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Fluorfenidine F-18 is a radionucleotide used in positron emission tomography (PET) imaging procedures.
Status:
Investigational
Source:
NCT00356434: Not Applicable Interventional Terminated Thrombophilia
(2008)
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Spiroxamine is a spirodecane derivative patented by German multinational pharmaceutical and life sciences company Bayer A.-G. as agrochemical fungicide. Spiroxamine acts as a sterol biosynthesis inhibitor with systemic activity. This active ingredient provides control of powdery mildew caused by the ascomycetous fungus, Uncinula necator (syn. Erysiphe necator) in grapes. In laboratory animals, the technical grade Spiroxamine was moderate to highly acutely toxic by the oral route and slightly acutely toxic by the dermal and inhalation routes of exposure. Spiroxamine was non-irritating to the eyes but moderately irritating to the skin. Spiroxamine caused an allergic skin reaction. Health effects in animals given repeated doses of Spiroxamine included effects on the liver, lining of the gastrointestinal and urogenital tracts, the eye and body weight. Spiroxamine did not cause cancer in animals and did not damage genetic material.
Status:
Investigational
Source:
NCT02232646: Phase 2 Interventional Withdrawn Urologic Malignancies
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Amcasertib is an orally administered investigational agent designed to inhibit cancer stemness pathways, including Nanog, by targeting stemness kinases. Amcasertib is undergoing multiple Phase I and Phase II studies as monotherapy and combination therapy for treating a range of tumor types.
Status:
Investigational
Source:
NCT04669067: Phase 1/Phase 2 Interventional Active, not recruiting Acute Myeloid Leukemia
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
p53 is a critical tumor suppressor and is the most frequently inactivated gene in human cancer. Inhibition of the interaction of p53 with its negative regulator MDM2 represents a promising clinical strategy to treat p53 wild-type tumors. AMG 232 is a potential best-in-class inhibitor of the MDM2-p53 interaction and is currently in clinical trials. Based on X-ray cocrystal structures a model of AMG 232 bound to MDM2 was developed. The model shows that the m-chlorophenyl, the p-chlorophenyl, and C-linked isopropyl fragments of AMG 232 bind to the Leu 26(p53), Trp 23(p53), and Phe 19(p53) pockets of MDM2, respectively. The carboxylic acid forms a salt bridge with His 96 and the isopropyl sulfone forms a novel interaction with the glycine shelf region of MDM2. AMG 232 in phase II in combination with trametinib and dabrafenib in subjects with metastatic melanoma; in phase I for the treatment of solid tumors, multiple myeloma and Acute Myeloid Leukemia.
Status:
Investigational
Source:
NCT03045861: Phase 2 Interventional Completed Infection, Human Immunodeficiency Virus
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02113163: Phase 1 Interventional Completed Diabetes Mellitus, Non-Insulin-Dependent
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03252938: Phase 1 Interventional Recruiting Solid Tumors
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01705483: Phase 1 Interventional Terminated Pharmacokinetics of ASP9853
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01832298: Phase 1 Interventional Completed Advanced Solid Tumor
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
HaiHe Biopharma (Shanghai HaiHe Pharmaceutical) is developing simmitecan, an ester pro-drug of chimmitecan for the treatment of cancer. Simmitecan is in phase I development for solid tumours and colorectal cancer in China. Simmitecan (L-P) is a water-soluble ester prodrug of chimmitecan (L-2-Z) with potent anti-tumor activities in different experimental animals. Chimmitecan，a novel CPT derivative, exhibited potent antitumor activities both in vitro and in vivo by inhibiting topoisomerase I.
